Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Liver biopsy consistent with NASH and cirrhosis (F4 fibrosis) according to the NASH Clinical Research Network (CRN) classification, in the opinion of the central reader~* Has the following laboratory parameters at the screening visit, as determined by the central laboratory:~  * Alanine aminotransferase (ALT) ≤ 8 x upper limit of normal (ULN)~ * Creatinine Clearance (CLcr) ≥ 30 milliliter/minute (mL/min), as calculated by the Cockcroft-Gault equation~ * HbA1c ≤ 9.5% (or serum fructosamine ≤ 381 micromole (μmol) if HbA1c is unable to be resulted)~ * International normalised ratio (INR) ≤ 1.4, unless due to therapeutic anti-coagulation~ * Platelet count ≥ 100,000/μL~Key Exclusion Criteria:~* Prior history of decompensated liver disease including clinical ascites, hepatic encephalopathy (HE), or variceal bleeding~* Child-Pugh (CP) score \> 7, as determined at screening, unless due to therapeutic anti-coagulation~* Model for End-stage Liver Disease (MELD) score \> 12, as determined at screening, unless due to therapeutic anti-coagulation~* Other causes of liver disease including, but not limited to, alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disorders, drug-induced hepatotoxicity, Wilson disease, iron overload, and alpha-1-antitrypsin deficiency, based on medical history and/or centralized review of liver histology.~* History of liver transplantation~* Current or history of hepatocellular carcinoma (HCC)~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SEL 6 mg (Type: EXPERIMENTAL): Randomized Phase: SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.~Open-Label (OL) Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase.
- SEL 18 mg (Type: EXPERIMENTAL): Randomized Phase: SEL 18 mg plus placebo to match SEL 6 mg for up to 240 weeks.~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase.
- Placebo (Type: PLACEBO_COMPARATOR): Randomized Phase: Placebo to match SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy